InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,310.73
(
0.05%
)
US TECH 100
18,107.20
(
-0.05%
)
Dow Jones
39,960.71
(
0.13%
)
Brent Oil
83.13
(
0.57%
)
Bitcoin
65,130.26
(
-1.71%
)
Post# of 251834
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119648
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 208066

Monday, 08/14/2017 9:12:08 AM

Monday, August 14, 2017 9:12:08 AM

Post# of 251834
OPTH’s third—(and final)—Fovista phase-3 fails:

https://finance.yahoo.com/news/ophthotech-announces-results-third-phase-103000016.html

The addition of 1.5mg of Fovista to an Eylea or Avastin regimen did not result in benefit as measured by the mean change in visual acuity at the 12-month time point.

The stock is -9%/PM, implying (surprisingly) that some investors still had hope for the Fovista program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up